Every year, counterfeit medicines cause harm to many patients, particularly in developing countries. This problem is being tackled by a joint project of the Tübingen-based Difäm and the Ecumenical Pharmaceutical Network (EPN) that aims to detect counterfeit medicines in developing countries with the help of local analytics. To this end, local centres are provided with […]

Positive economic news is rare in times of crisis. This makes this news from Graz all the more pleasing: an order worth millions of euros gives SHS portfolio company Tyromotion a positive outlook for the future.

Tübingen-based industry investor SHS acquires minority share in formulation specialist Develco Pharma Develco specializes in the development, approval and production of innovative and generic specialty drugs and offers a unique and broad set of formulation technologies for orally administered medicines with specific substance-release profiles Develco operates a state-of-the-art production facility of its own in Germany […]

While the EU is significantly raising approval hurdles with the MDR, the US is putting medtech innovations in the fast lane with the Breakthrough Devices Program By: Dr André Zimmermann, partner at Tübingen-based industry investor SHS. He has developed global connections in the medical technology sector as a business development expert. Putting the brakes on […]

Unquote reports on the sale of our portfolio company puracon to the precision machining business Klingel medical metal, which is a portfolio company of IK Investment Partners.

SHS Gesellschaft für Beteiligungsmanagement mbH, based in Tübingen, is selling its shares in puracon GmbH to Klingel medical metal GmbH, a portfolio company of IK Investment Partners. With 600 employees, Klingel Group is one of the leading companies in the field of precision machining of high-strength materials such as stainless steel and titanium for the […]

The trade magazine of going public portrays SHS (page 50-51) as one of the oldest players in the financing of German life sciences companies, start-ups and SMEs, with a focus on medical technology, diagnostics, suppliers and digital health.

Coronavirus, digitalisation, MDR, Brexit – companies in the medical technology sector face major, capital-intensive challenges. What is key at this stage? By: Dr André Zimmermann, partner at Tübingen-based industry investor SHS. He has developed global connections in the medical technology sector as a business development expert. Coronavirus takes its toll It is autumn and, as […]

Coronavirus, digitalisation, regulation, Brexit: What are the challenges facing the medtech sector, and why do we need a solid equity position now in particular? Dr. André Zimmermann is a partner of Tübingen-based industry investor SHS. An expert in business development, Dr. Zimmermann has superb connections to the medtech sector. With a PhD in the natural […]

Enzyme manufacturer c-LEcta is one of the fastest-growing biotech firms in Germany and an important supplier to numerous makers of coronavirus vaccines. c-LEcta products are also used by worldwide pharmaceutical firms and food corporations. In an interview, c-LEcta founder Dr. Marc Struhalla explains the role of the enzyme DENARASE® in the production of vaccines to […]

In the field of neuro-rehabilitation, for instance following a severe stroke or other neurological diseases, learning to walk again is crucially important. Robot-controlled gait trainers help the affected patient to stand and walk on his or her own again. Yet the LEXO® put into operation by the Wolletzsee rehabilitation clinic, north-east of Berlin, is no […]

The InnoHealth USA 2021 campaign is part of the ‘Research in Germany’ initiative of the German Federal Ministry of Education and Research (BMBF). The entire campaign is being carried out by the Fraunhofer-Gesellschaft. Our colleague Dr. André Zimmermann has been appointed to the jury of InnoHealth USA 2021 and will provide expert supervision and evaluation […]